Results for the quarter and nine months ended on 31st Dec 2025
Awaiting price reaction for this filing.
The Board of Sarda Proteins Limited approved unaudited results for Q3 FY26 and 9M FY26 on 14 February 2026. Revenue from operations for the December quarter collapsed to just Rs 25 lakhs, down sharply from Rs 2,405.10 lakhs in the same quarter last year (roughly a 99% YoY decline). For the nine months ended December 2025, revenue fell about 36% to Rs 1,550.84 lakhs versus Rs 2,419.10 lakhs a year ago. The company swung to a loss before tax of Rs 11.81 lakhs in Q3 (vs a profit of Rs 9.70 lakhs YoY) and a 9-month loss of Rs 20.69 lakhs (vs a profit of Rs 12.20 lakhs). Basic EPS turned negative at Rs (0.68) for the quarter and Rs (1.20) for nine months. The statutory auditor (A H Mandaliya & Associates) issued an unmodified limited review report with no qualifications.
The dramatic revenue drop and return to losses point to significant operational weakness, which is likely to weigh negatively on investor sentiment and the stock price despite the clean auditor opinion.